We are live on ! Find out more
ABMD

Abiomed Inc

Delisted

ABMD was delisted on the 21st of December, 2022.

405 hedge funds and large institutions have $11.5B invested in Abiomed Inc in 2018 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 112 increasing their positions, 162 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more funds holding in top 10

Funds holding in top 10: 615 (+9)

133% more first-time investments, than exits

New positions opened: 84 | Existing positions closed: 36

57% more capital invested

Capital invested by funds: $7.31B → $11.5B (+$4.15B)

12% more funds holding

Funds holding: 361405 (+44)

6% less call options, than puts

Call options by funds: $87.8M | Put options by funds: $93.8M

31% less repeat investments, than reductions

Existing positions increased: 112 | Existing positions reduced: 162

Holders
405
Holders Change
+44
Holders Change %
+12.19%
% of All Funds
9.28%
Holding in Top 10
15
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+150%
% of All Funds
0.34%
New
84
Increased
112
Reduced
162
Closed
36
Calls
$87.8M
Puts
$93.8M
Net Calls
-$6.01M
Net Calls Change
+$4.3M

ABMD Hedge Fund Activity: Q1 2018 in Review

405 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Abiomed Inc (ABMD) for Q1 2018, worth a combined $11.5B — up 57% from $7.31B a quarter earlier.

Buyers outnumbered sellers: 84 funds opened new ABMD positions and 36 closed out — a net gain of 48 holders — while 112 added to existing stakes and 162 trimmed.

The largest buyer was Winslow Capital Management, opening a new position worth an estimated $199M. The largest seller was Essex Woodlands Management, cutting an estimated $113M.

  • 405 institutional investors held Abiomed Inc (ABMD) as of Q1 2018, up from 361 in Q4 2017.
  • Funds reported $11.5B of Abiomed Inc stock for Q1 2018, up 57% quarter-over-quarter.
  • 84 funds opened new Abiomed Inc positions in Q1 2018 and 36 closed out, a net change of +48 holders.
  • The largest Abiomed Inc buyer in Q1 2018 was Winslow Capital Management, an estimated $199M added.
  • The largest Abiomed Inc seller in Q1 2018 was Essex Woodlands Management, an estimated $113M sold.

Based on aggregated 13F filings for Q1 2018.